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ABSTRACT 
The scientific evidence of Hyperbaric Oxygen Treatment is despite the fact that the 
hyperbaric method has been in use since 1662 still under debate. At Karolinska 
University Hospital the method has been under the supervision of the department of 
anesthesia and intensive care since 1990. The number of treatments increased slowly 
and reached a total of approximately 3000 /year in 2008 (fig 1) although evidence of 
the efficacy slowly developed. The facility develops towards HBO for intensive care 
patients, a real challenge because of the demand for high technology in high-pressure 
and fire hazard surroundings. Infectious disorders such as severe soft tissue infections 
or postoperative neurosurgical infections have slowly developed to make a large part of 
the patients (fig 1). In 2005 a committee from Karolinska Institutet inspected the 
facility and identified among other things the lack of clinical research projects. 
My thesis was therefore started first with a description of one of our large patient 
groups (paper I) and with the aim to perform clinical research projects for severe soft 
tissue and neurosurgical infectious patients using prospective randomized protocols. 
The lack of evidence for the correct dosage of HBOT and the lack of non-invasive 
methods to measure oxygen content in tissues during treatment soon became evident. 
These issues made the efforts to construct conclusive prospective protocols seem 
premature and the focus of the thesis changed to help providing a solid basis for future 
HBO studies. We tested 2 non-invasive methods to monitor oxygen content in target 
tissues, NIRS and PPG, and developed a new method (HOPAN) to make it possible to 
treat intensive care patients according to patients’ demands without risk of DCS for 
attendants. NIRS measurements provided focus on soft tissues and PPG on bone 
tissues. NIRS (paper II) and PPG (paper III) have been tested with healthy subjects 
during NBO and HBO. NIRS was found to follow the inhaled oxygen within minutes.  
Using PPG technique we found individual changes in blood flow following the inhaled 
oxygen also within minutes. NIRS is a commercially available method though not yet 
approved for use in hyperbaric chambers. PPG equipments for clinical use are not yet 
available. 
To make it possible to test HBO doses with the focus on patient need instead of the 
conventional compromise between the attendants safety and patient need we 
constructed a protocol with nitrox breathing for attendants (HOPAN, study IV). In our 
retrospective evaluation the method we found the method to be safe for both patients 
and attendants. 
 
Both the tested non-invasive oxygen monitoring methods and the new HBO method 
will hopefully make a contribution to the development of good clinical prospective 
randomized research protocols. 
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1 INTRODUCTION 
 
Hyperbaric Treatment has been suggested as early as 1662 1. The method started as 
treatment of diving related symptoms in the 19th century 2 and has been developed by 
military marine forces and by civilians. The two lines, though using the same drug – 
Oxygen –  and the same pressure and method (hyperbaric chambers) have over the 
years separated into diving (diving and submarine rescue) and hyperbaric medicine.  
The protocols used for hyperbaric oxygen treatment are originally designed for healthy 
divers or for submarine rescue (also healthy soldiers).  
Oxygen was discovered in the 1770 ties (Scheele 1772 and Priestly 1775) and the use 
of HBO for different disorders spread starting in France and then to the large cities of 
Europe during the 19th century 3 . HBO came into clinical routine use in the 1960 ties 
by the Dutch surgeon Boerema. During the same decade (1967) UHMS was formed to 
further science in this field.  
 
Oxygen was, in Sweden, registered as a drug as late as 2004 4, although it had already 
been clinically available and in use since world war I. As the drug was not scientifically 
evaluated or registered through the normal procedure by the medical procedure agency 
(MPA) or the Food and Drug Administration (FDA) before it was taken into use it has 
never been submitted to all of the tests modern drugs are submitted to. The 
pharmacokinetics and pharmaceutical knowledge of the drug is not fully understood 
although almost every medically trained person has personal experience of this drug. 
As with many others drugs different pharmaceutical effects are produced with different 
doses, and the use of oxygen has conventionally been divided into two different levels 
with totally different pharmacology. Normobaric Oxygen (NBO) = Oxygen breathing 
at sea level, i. a maximum dose is 100%=101kPa and Hyperbaric Oxygen (HBO) = 
oxygen (usually 100%) breathing at a pressure higher than sea level (> 101 kPa, > 1 
ATA) (HBO definition from UHMS5).  This thesis is focused on HBO.  
 
HBOT has been under debate for many decades and how, where and when to use the 
treatment, evidence-based, has not yet come to a conclusion. Several studies with a 
high level of evidence have recently been performed, showing results in diabetic foot 6, 
carbon-monoxide poisoning 7, radio-induced proctitis 8. Cochrane reports have been 
published showing favorable result for the use of HBOT in late radiation tissue injury 9 
One of the most commonly internationally accepted list of indications is published by 
Undersea &Hyperbaric Medical Society (UHMS) since 1977 and revised every 2nd-4th 
year 5. There is also a European list of indications from a Consensus Conference on 
HBO 2004 10 where an evidence-based approach was applied. The lists of indications 
consists of, among others, a number of infectious conditions such as gas gangrene, 
intracranial abscess, necrotizing soft tissue infections and refractory osteomyelitis. In a 
Cochrane progress report 11, an evaluation of HBO treatment of severe soft tissue 
infections is made. The report is inconclusive and points at a number of difficulties 
i.e. definitions of the disease, dose of HBOT (i.e. treatment pressure, duration, 
number of treatments). To these difficulties can be added the lack of valid, non-
invasive monitoring methods of the oxygen content in tissues to verify that a correct 
dose of the drug really reaches the target. 
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At the HBO unit of Karolinska University Hospital we have treated a number of 
infectious diseases during 2005-2010 (fig 1). Severe soft tissue infections (SSTI) are 
relatively rare 12, although the HBO unit has seen 288 adult patients with SSTI 
requiring intensive care during 1995-2010 (fig 2). 
  
 
 
Fig. 1 
HBO Treatments of infectious disorders at the Hyperbaric unit of Karolinska University Hospital 
 
 
Our mortality (57% 1996 -7,7% 2010) during 1995-2010 for severe soft tissue 
infections compared to the expected mortality by APACHE II score (median 
APACHE II of CNF =16, 1998-2008 13 -> expected mortality 26%, median APACHE 
II of SSTI= 23, 2005-2010 ->expected mortality 30-40%) suggests improved and 
good results. Other HBO-units have reported similar results 14.  
 
 
 
 
 
 
 
Fig. 2 
Patients with SSTI at treated at the HBO unit of Karolinska University Hospital, 1995-2010. 
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In 2005 a committee from Karolinska Institutet inspected the facility and pointed, 
among other things, at the lack of clinical research projects. 
 
The author have reported retrospective clinical results from the unit as case-reports, 
abstracts, posters at international, european and national conferences at 17 occasions 
during 2000-2010, with very little or no response 13, 15-21. The report and the response 
from the multiple abstracts made several colleagues including me realize the need for 
scientific evidence of HBO rather than the routine of retrospectively reporting clinical 
experience. A research schedule was planned with a prospective randomized study of 
intensive care patients with severe soft tissue infections (SSTI). While planning the 
protocol of the study it became evident that the basics for an evidence-based HBO 
protocol was lacking and the research schedule was gradually changed to studies of 
monitoring methods and dose of HBOT. 
 
 
As tissue hypoxia is intrinsic to the problem in severe soft tissue infections and 
osteomyelitis as well as many of the other indications for HBOT, the lack of reliable 
and suitable monitoring methods of the oxygen content in target tissues makes 
evaluation and dosage of the method difficult. Inadequate tissue oxygenation may exist 
while vital signs, such as blood pressure, heart rate and arterial oxygen saturation as 
measured with pulse oximetry (SpO2) appear normal. Near-infrared spectroscopy 
(NIRS), like pulse oximetry, measures the changes in blood oxygen saturation non-
invasively 22. The difference between the two methods is that while pulse oximetry 
monitors the systemic oxygen saturation, tissue oxygen saturation (StO2), as measured 
with NIRS, monitors changes in the regional oxygen saturation. This makes NIRS an 
interesting method to evaluate oxygen content in the tissues during both NBO and HBO 
administration, whereas SpO2 quickly reaches the maximum value of 100% when the 
oxygen content in the breathing gas is elevated. 
 
 
At our unit we started treatment of cranial osteomyelitis as a result of a discussion with 
professor Mathiesen (department of neurosurgery) on the subject of lack of available 
operation theatres for surgery.  It was suggested that by using HBOT as an adjunct to 
antibiotics for postoperative neurosurgical infections some of the removal of infected 
bone cranioplasties could be inhibited thus making more room for other surgical 
interventions. The results were published 2002 23 (paper I) and reprinted 2008 because 
of the originality of the study.  Infectious conditions in bone are difficult to monitor and 
the knowledge of HBO mechanisms and dosage are as a consequence small.  
 
 
Hemodynamic changes to hyperoxia in other tissues than bone have been extensively 
studied but the underlying mechanisms are still far from completely understood 24. 
There is at present no non-invasive clinically available method to evaluate oxygen 
content in bones, which makes it very difficult to follow clinical progress of HBO 
treatment in these tissues. We tested (paper III) a newly developed non-invasive 
method, photoplethysmography (PPG), where changes in pulsatile blood flow within 
the patellar bone and overlying skin were recorded continuously. PPG has been used to 
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monitor blood flow in skin and muscles 25-27, and hemodynamic sensing in implanted 
devices 28. It has also been shown that experimental induced changes in pulsatile blood 
flow within the patellar bone are possible to study using the PPG technique 29-31. 
Monitoring changes in bone blood flow during oxygen treatment could be of value in 
the study of physiological reactions related to HBOT, although the method has not yet 
been evaluated for hyperbaric use.     
 
In a multiplace chamber (pressurized with air), patients breathe oxygen via a ventilator, 
hood or a mask, usually assisted by chamber attendant(s) breathing the chamber air. 
Decompression Sickness (DCS) is therefore a possible complication for HBO 
attendants 32-34. To reduce this risk, decompression protocols are calculated using 
algorithms developed and originally tested for diving 35. A monoplace chamber 
(pressurized with 100% oxygen) where the patient breathes oxygen without a mask or 
hood, is most commonly used for conscious and communicable patients. Usually there 
is neither space nor need for chamber attendants inside a monoplace chamber, and the 
treatment protocol can be designed according to the patient’s needs exclusively.  
 
As the HBO patients breathe 100% oxygen, they will not accumulate nitrogen and thus 
not be at risk of DCS. Apart from oxygen toxicity risk, duration of HBOT for the 
critical care patient is limited by other essential treatments and examinations (e.g., 
imaging, surgery and dialysis). All protocols are therefore a balance between oxygen 
treatment for the patient, oxygen toxicity and chamber attendants’ risk of DCS.  
 
Historically, protocols were aimed at treatment of divers suffering from DCS 32-33. For 
most infectious patients, a reduction or absorption of gas bubbles is irrelevant; instead, 
the increased delivery of oxygen to target tissues is paramount. A protocol with a 
flexible duration, ability to adapt to time constraints in the clinical program and shift 
balance towards optimal care of the patient (while keeping the safety of the attendants 
well within accepted limits) would be ideal. 
 
We developed an HBOT protocol (HOPAN, paper IV) that enables the critical care 
patients in multiplace chambers to receive at least the same dose as the patients in 
monoplace chambers still with a minimal risk for attendants and keeping the option of a 
direct ascent to surface at all times. In this protocol attendants breathe nitrox (oxygen 
enriched air), a method known to divers to prolong time at depth since the1950ties 2. 
Attendants breathing nitrox have been in routine use in other HBO facilities, but the 
experiences have not yet been published. 
 
Oxygen constitutes a basic need for all cells in the human body, which means there are 
many physiological mechanisms including protective mechanisms involved in the 
metabolism of this drug. It is difficult to find the interest and economics to investigate 
an already widespread drug, that a wide majority of users already have a very definite 
opinion on how and why to use. It is therefore easy to understand why the scientific 
evidence of HBO and NBO is lacking. It is also easy to understand why there is a really 
huge need to investigate the evidence base for the wide use of oxygen both as NBO and 
HBO. 
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Combining the two non-invasive oxygen monitoring methods and the new HBOT 
protocol we think there are increased possibilities to plan good prospective randomized 
studies to answer some of the issues regarding dosage and indications of HBO. This 
may include monitoring oxygen in target tissues - making the dosage for each patient 
individual. 
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2  AIMS OF THE PRESENT STUDY 
 
The general aim was to find monitoring methods and flexible HBOT protocols, based 
on the patients’ need of oxygen, to investigate the possibility to use of HBOT in 
severe infectious conditions. 
 
Our specific aims were: 
 
1. To retrospectively report the additional use of hyperbaric oxygen (HBO) therapy for 
infections after craniotomy or laminectomy during 1996-2000 at the HBO unit of 
Karolinska University Hospital. 
 
2. To examine if near-infrared spectroscopy (NIRS) would make it possible to monitor 
oxygen changes in target tissues (StO2) in healthy subjects during NBO and HBO 
administration.  
 
3. To investigate, if photoplethysmographic technique (PPG), can be used to monitor 
individual changes in pulsatile blood flow in bone and in skin in healthy subjects during 
NBO and HBO administration.  
 
4.  Evaluate the newly designed HBOT protocol (HOPAN) in use in out unit during 
2008- march 2009. The protocol’s aimed at enabling an equal or higher dose of Oxygen 
to critically ill patients compared to other patients while maintaining a low risk of 
decompression sickness (DCS) for attendants.  
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3 MATERIALS AND METHODS 
 
 
3.1 STUDY I: HYPERBARIC OXYGEN TREATMENT OF 
POSTOPERATIVE NEUROSURGICAL INFECTIONS 
 
Retrospective non-randomised clinical study 
HBOT was used, in a pilot study, as an alternative to standard surgical intervention for 
postoperative infections in the neurosurgical department at Karolinska University 
Hospital. 39 consecutive patients referred for HBOT with a clinical diagnosis of 
postoperative neurosurgical infection during 1996 to 2000 were included.  
The study involved review of medical records, office visits, and telephone interviews. 
Infection control and healing without removal of cranioplasties or foreign material were 
considered a successful result.  
Medical records were followed for a minimum of 6 months (mean 27, range 6-58) after 
completed HBOT or until failure. 
 
The study has expanded to 72 patientens, 1996-2003 after publication. These results 
have been reported as abstract at scientific meetings 20.  
 
 
 
3.2 STUDY II: NEAR-INFRARED SPECTROSCOPY DURING 
NORMOBARIC AND HYPERBARIC OXYGEN BREATHING IN 
HEALTHY SUBJECTS  
 
Semi-Blinded test using healthy volunteers: Validation of near-infrared spectroscopy 
(NIRS) as a non-invasive monitor of tissue saturation (StO2) during HBO 
Tests were performed in a hyperbaric multi-place chamber (Kockums, Sweden) using 
hoods (CASTAR, STARMed) supplied with either air or oxygen during the 
experiment. Subjects were positioned in a semi-recumbent position; test protocol was 
started after 10 minutes of rest.  
 
Subjects (9 healthy volunteers), were blinded as to whether they breathed air or oxygen. 
Different O2 partial pressures were administered in the following 10 minute intervals:  
NBO: 21 kPa (air), 101 kPa (100% O2), 21 kPa. 
HBO: 59 kPa (air), 280 kPa (100% O2), 59 kPa. 
 
Tissue oxygenation was monitored with an InspectraTM StO2 monitor (Hutchinson 
Technology, MN, USA) inside the chamber using a probe placed on the thenar 
eminence (thumb). The monitor was tested for use under hyperbaric conditions 
(maximum 3.5 bars) according to a risk analysis protocol in cooperation with the local 
medical technical department.  
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Heart rate and blood pressure were monitored with a Propaque monitor 106 EL 
(Protocol Systems Inc, Beaverton Oregon, USA), also inside the chamber.  
Data were averaged over last 5 minutes at each pressure.  
The volunteers were all recreational divers; eight males and one female.  
 
 
3.3 STUDY III: BONE AND SOFT TISSUE BLOOD FLOW DURING 
NORMOBARIC AND HYPERBARIC OXYGEN BREATHING IN 
HEALTHY SUBJECTS 
 
Semi-Blinded test using healthy volunteers: Validation of a new photoplethysmographic 
(PPG) method as a non-invasive monitor of bone and soft tissue blood flow during 
HBO 
Tests and protocols were performed exactly as in study II, above. All performed in the 
afternoon or evening. The chamber was ventilated to hold an environmental 
temperature of 20 - 25 ºC.  
 
Subjects (11 healthy volunteers, 2 female) all recreational divers, were blinded as to 
whether they breathed air or oxygen during NBO and HBO. Different O2 partial 
pressures were administered in the same 10 minute intervals as in study II, above.  
A two channel PPG instrument (Department of Biomedical Engineering, Linköping 
University, Sweden) and a PPG probe were used to continuously record blood flow 
changes in the patellar bone and in the skin overlying the patella. The probe was 
connected to the PPG instrument outside the chamber using a pass-through in the 
chamber wall. 
 
The pulse-by-pulse amplitude of the AC component of the PPG signal was 
subsequently extracted with dedicated software (Daquhura 1.3, Linköpings Tekniska 
Högskola 1995). The PPG signal was later analyzed using software (MATLAB, 
R2006b). A base-line, pre-oxygen value was calculated from 30-60 seconds peak-to-
peak recordings, both during NBO and HBO. When the bone blood flow was at its 
lowest level, ~ after 2 min, a 30 second peak-to-peak recording was used as oxygen 
breathing value.  
 
Differences in individual data on assessments of pulsatile blood flow in bone and skin 
were expressed as percentage of changes between air breathing and NBO/HBO 
respectively.  
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3.4 STUDY IV: NITROX PERMITS DIRECT EXIT FOR ATTENDANTS 
DURING EXTENDED HYPERBARIC OXYGEN TREATMENT 
 
Retrospective study of patient medical records and a questionnaire to attendant. 
Experiences from attendants and patients of a new protocol, HOPAN, for HBOT. 
 
 
 
 
Fig 3.  
LTP (local treatment protocols) and maximum HOPAN. 
Thick line = 175 minutes multiplace LTP. Large interrupted line = 105 minutes multiplace LTP.  Small 
interrupted line = maximum 200 minutes HOPAN. Thin line = 100 minutes monoplace LTP. 
  
 
 
All treatments were performed in a multiplace chamber (HAUX Qaudro 3200). A 
minimum of two attendants inside and two outside the chamber were present 
throughout each protocol. Information regarding patients and attendants having 
participated in HOPANs were collected from the hospital patient and HBO unit 
documentation systems and medical records. 
 
 
HOPAN 
HOPANs were used occasionally during 2008-march 2009 under the supervision of at 
least one of the authors of the study. HOPAN were calculated using both the Bühlmann 
mathematical model (Bühlmann ZHL16B) and the variable permeability model (VPM). 
Both calculations were made using a commercially available program (Decoplanner 
version 3.1.4).  
 
Attendants: breathed nitrox (using a HAUX mask) or chamber air (off mask), they were 
allowed to participate in one chamber “dive” per 24 hours. Cycles of 15 minutes of 
nitrox breathing followed by 10 minutes of chamber air were administered, using the 
hospital supply of medical oxygen and air, mixed continuously at a ratio of 1:1 (60.5% 
O2). Treatment duration of up to a maximum of 200 minutes at 2.8 ATA was allowed; 
no randomization was carried out.  
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Expired oxygen was measured intermittently with a mobile oxygen detector though not 
documented.  
 
An anonymous questionnaire was sent to attendants (n = 59; with study directors 
excluded n = 56) having participated inside or outside chambers during an HOPAN 
once the study period was finished. The questionnaire included one part with questions 
regarding LTP and a second repeating the questions for HOPAN. The questions 
included earlier experience of HBO/diving, DCS symptoms, comfort and safety. All 
symptoms or complaints were subjectively graded (1-10). The answers and separate 
written approval to participate in the study were sent to a study collator with no 
knowledge of the HBO unit or attendants. The answers were then transformed into a 
data file (with no participant identifiers) and sent to the study directors for further 
analyses. 
 
Patients: breathed cycles of pure oxygen for 20 minutes interrupted by 5 minutes of air  
through a ventilator, hood (CASTAR, STARMed) or mask (HAUX). They were 
monitored according to clinical routine. Patients received local treatment protocols 
(LTP) as well as HOPANs in their HBOT series.  
 
 
 
 
 
 
Fig.4 
Number of HOPANs and of LTP for patients in the study (n=30). 
 
 
 
Patients’ medical records were followed for six months after the HBOT series was 
finished. 
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4 RESULTS 
 
4.1 STUDY I: HYPERBARIC OXYGEN TREATMENT OF 
POSTOPERATIVE NEUROSURGICAL INFECTIONS 
 
Successful results were achieved for 27 of 36 patients (n=39), with a mean follow-up 
period of 27 months (range 6–58). One patient discontinued HBOT because of 
claustrophobia, and two could not be evaluated because of death prior to the 6 month 
minimum follow-up time. There were no major side effects of HBO treatment. 
Patients were divided into 3 different groups according to their neurosurgical disorder. 
 
Group 1 (uncomplicated cranial wound infections, n=15), 12 of 15 patients healed 
succefully with retentained autologous cranioplasties. 
 
Group 2 (complicated cranial wound infections, with risk factors such as malignancy, 
radiation injury, repeated surgery, or implants, n=16), all except one infection resolved; 
three of four autologous and three of six acrylic cranioplasties could be retained. 
 
Group 3 (spinal wound infections, n=7), all infections resolved, five of seven without 
removal of implants.   
 
Additional data (fig 5) describes the cultures found in the 3 groups, this was not 
included in the original publication. 
 
The study concludes that HBO treatment is an alternative to standard surgical removal 
of infected cranioplasties and implants. 
 
 
 
Additional data was also published as an abstract at the annual scientific meeting of 
UHMS 2004 20. 72 consecutive patients (including the patients in the published study) 
treated during 1996-2003.  
 
Group I: 19/24 healed with retained autologous cranioplasties.  
 
Group II: 12/25 healed with retained cranioplasties.  
 
Group III: 12/14 healed with retained implants/cerebral shunts. 
 
Group IV brain abscesses/empyemas: 9/9 healed. 
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Fig. 5 
Results from cultures of wounds in the 3 original groups (n=39).  
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4.2 STUDY II: TISSUE OXYGENATION MEASURED WITH NEAR-
INFRARED SPECTROSCOPY DURING NORMOBARIC AND 
HYPERBARIC OXYGEN BREATHING IN HEALTHY SUBJECTS 
 
When switching from air to NBO StO2 increased from 83% (82-85%, median and 
interquartile range) to 85% (84-87%) (P\0.01), and when switching from air at pressure 
(59 kPa O2) to HBO (280 kPa), StO2 increased from 85% (85-86%) to 88% (87-89%) 
(P\0.001). There was no difference between baseline StO2 while air breathing before 
NBO or after decompression.  
The main finding of the study was that tissue oxygen saturation (as measured by NIRS) 
increased significantly, but did not reach 100% during both NBO and HBO. The results 
suggest that this method could be used to monitor changes in tissue saturation during 
HBOT. 
 
Statistical analysis: Nonparametric statistical procedures were performed throughout 
the study unless otherwise stated. Median values of NIRS (%) during the last 5 min of 
the different pressure periods were compared for the different subjects. The Friedman 
test (nonparametric repeated measures ANOVA) was applied with Dunn’s multiple 
comparison test.  
 
 
 
4.3 STUDY III: BONE AND SOFT TISSUE BLOOD FLOW DURING 
NORMOBARIC AND HYPERBARIC OXYGEN BREATHING IN 
HEALTHY SUBJECTS  
 
Pulsatile patellar- and skin- blood flow decreased during the first 2-3 minutes of NBO 
and HBO.  
The decrease in blood flow was: 
NBO: 32% ±15 in bone and 36% ±18 (mean SD, p<0.0001) in skin. 
HBO: 22% ±18 in bone and 21% ±25 (mean SD, p< 0.0344) in skin.  
Blood flow returned to base-line levels within 5-8 minutes.  
The results suggest that PPG could be used to monitor individual changes in bone and 
skin blood flow during HBOT.  
 
Statistical analysis: Blood flow changes were expressed as percentage of the pre-
oxygen level and presented as mean (95% confidence interval). T-test for dependent 
samples was used analyzing blood flow changes. The level of significance was set at P 
<0.05.  
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4.4 STUDY IV: NITROX PERMITS DIRECT EXIT FOR ATTENDANTS 
DURING EXTENDED HYPERBARIC OXYGEN TREATMENT 
 
HOPAN treatment protocols (n=88) were used during 2008-march 2009, 64 attendants 
(including three of the study directors) breathed nitrox on 142 occasions. Thirty patients 
were treated with a combination of LTP (n = 336)/multiplace LTP (n = 125) and 
HOPANs. 
 
 
HOPAN:  
duration:139.5 minutes (median, range 55-167 minutes).  
time at treatment pressure (2.8 ATA ): 110 minutes (median, range 45-145).  
UPTD for attendants: 174 (median, range 130-232). 
UPTD for patients: 403 (range 163-520). 
 
LTP/multiplace LTP: 
duration: 100 minutes/105 minutes (median, range 100 – 175/105 – 175).  
time at treatment pressure (2.8 ATA ): 60 minutes/65 minutes (median, range 0 - 90/60 
- 65).  
UPTD for attendants: 90.3/20. 
UPTD for patients: 266 /423.  
UPTD for LTP in monoplace chambers: 266.9 (2.8 ATA) resp. 238.2 (2.5 ATA). 
 
 
ATTENDANTS:  
5 were excluded (3 had participated in other experimental tables, 2 could not be 
reached). There were 35 physicians, 19 nurses and 5 others; ages 25 to 60-plus, 26 
females. Total number of exposures in multiplace chambers (LTP and HOPAN) of the 
attendants (n = 59), historically and during study period, was 1808 (median 20, range 1-
162). ). The median number of HOPANs (inside the chamber) each attendant 
participated in was 2 (range 1-24). 56/64 attendants (study directors excluded) received 
an invitation to participate in the study and a questionnaire, 31 responded. 
 
LTP:  
24/31 minor symptoms, 10/31 (paresthesias, tingling of skin) 14/31 (tiredness, 
headache, slight dizziness). 
5/31 joint pain (two severe -5 and 8/10).  
 
HOPAN:  
1/31 minor symptoms (tiredness). 
1/31 mild joint pain (3/10).  
 
There were no complications (DCS or symptoms of oxygen toxicity) reported or treated 
among attendants. Study of the HBO unit’s archive showed no recorded symptoms or 
complaints from any attendant, neither historically nor during the study period.  
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PATIENTS:  
30 patients were treated with HOPANs in combination with LTP. Each patient received 
a median of 11 (range 1-51) HBOT sessions, of which the median number of HOPANs 
were 2.0 (range 1-10). No complications were documented. Six-month follow-up 
showed that mortality for critical care patients having received at least one HOPAN 
was 1/20, study period 2008-march 2009. The number of adult critical care patients 
treated with HBOT (including HOPAN) in Karolinska University Hospital during 
2008-2009 was 64, with a mortality rate of 4/64 (fig 2 in introduction). 
 
 
It is suggested that nitrox breathing for chamber attendants provide flexible HBOT for 
patients at 2.8 ATA for up to 200 minutes, facilitating  future studies of HBOT dosage.  
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5 GENERAL DISCUSSION 
 
Oxygen as a drug 
 
The use of oxygen in medicine started long before it was recognized as a drug 36. The 
process of bringing oxygen into clinical practice can rather be described as empirical 
although based on sound physiological principled and a logical rationale 36.  In Sweden 
oxygen was recognized by MPA/LMV as late as 2004 4.  A lot of documentation is 
lacking such as maximum dose, optimal/correct dose for many of the different 
conditions the drug is used in and the indications have not been subjected to the modern 
evidence-based procedures of randomized studies before it was taken into a widespread 
use. Despite the lack of knowledge there are some facts known and there is a lot of 
experience of the use of oxygen.  
 
The effects of HBO (defined as oxygen breathing at a higher than ambient pressure 
approximately 1.0 ATA at sea level, commonly an increase of 0.5-1.8 ATA for 
therapeutical use 5 is vastly different from those when the drug is used as NBO. The use 
of small quantities of supplementary oxygen (even as low as 2 liters of oxygen/minute 
at 1 ATA nasally) have been questioned in a recent study 37-38. 
 
The physiologic effects of HBO include 5, 39 : 
- intravascular and tissue gas bubble reduction 
- improved tissue oxygenation 
- vasoconstriction 
- increased antimicrobial activity40 
- modulation of inflammation and immune function39, 41 
- promotion of angiogenesis42-43 
- increased bone turnover 44 
- improved osseointegration and reduction of implant 45-46. 
 
The immediate reactions of HBO on bone blood flow have not been studied (to our 
knowledge) or published prior to our study.  
 
 
 
HBO-dose  
 
An international standard for documentation of oxygen dose the patient is scheduled for 
or has received does not exist yet. National Board of Health and Welfare and Medical 
Procedure Agency in Sweden produce guidelines on the safe use of drugs, one of their 
important issues is how to properly document a drug and the dose given to a specific 
patient. The guidelines regarding oxygen are scarce and non-specific especially if you 
include HBO doses 4.  Some of the units conventionally used include added 
liters/minute to ambient air, % oxygen (usually mask breathing at sea level), bars, 
ATA, kPa and sometimes HBO-protocols are referred to i.e. USN table 6, HOPAN, 
LTP. The correct protocols of HBO to be used are very scarcely evaluated 47.  
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Lack of reliable and suitable methods for monitoring the oxygen content in the target 
tissues makes evaluation and dose determination of HBO difficult. Many questions 
remain to be answered: For example, is pressure or duration of HBO of greatest 
importance, or perhaps both combined? It is also not clear how often the treatment 
should be repeated 35, 47. HBO dose varies between different treatment centers; and the 
appropriate dose of oxygen for the patient is not always the main issue, since logistics 
and staff safety have to be considered.  
 
During our retrospective studies of HBO treated patients and the preparation of a 
prospective randomized protocol we found that the intensive care patients consequently 
received a lower dose of oxygen during HBO than other patients (fig 6, monoplace LTP 
contra multiplace LTP). Until further studies verify optimal pressure and duration of 
HBO we consider it rational to treat critical care patients with similar tables as 
monoplace patients and not less duration at treatment pressure. 
 
 
 
 
 
 
Fig.6.  
Percent time (total HBO2T series) at treatment pressure (2.8 ATA) for each patient in study IV (n=30), 
separated into the different protocols used. Black dots denote HOPAN; transparent dots = multiplace 
LTP; and triangles = monoplace LTP. 
 
 
 
 
At the UHMS annual scientific meeting 2010, dr Neil Hampson addressed this problem 
and suggested the use of ATA-hours of oxygen to describe the total dose of HBO the 
patient has received 47. ATA-hours is calculated using the very simple formula “time of 
pure oxygen breathing at treatment pressure (hours) x treatment pressure (ATA)” 
(personal communication with dr Hampson, august 2010). 
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Below is dr Hampson’s suggested ATA-hours applied on the patients in paper IV, SSTI 
adult patients in Intensive Care (fig 6, 7, 8).  
 
 
 
 
Fig. 6. 
Total ATA-hours compared to APACHE II score for patients (20/30) in paper IV. For some of the 
patients APACHE II score has not been documented, they are not described in this figure. We cannot, 
from these data, establish any correlation between severities of disease to received HBO-dose. 
 
 
 
 
 
 
 
Fig. 7. 
Total ATA-hours compared to the number of treatment days for the patients (n=30) in paper IV.  
 
 
 
 
Our clinical experience (Study I, IV) regarding HBOT dose indicates that infection 
control and establishment of the healing process can be quite rapid and that many 
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patients continue to exhibit improvement after cessation of HBOT. For other patients a 
longer treatment period might have been beneficial, future refinements could include 
individual monitoring of HBO response to make a tailor-customized dose possible.  
 
Many HBOT facilities have reported their experiences with HBOT as an addition to 
modern intensive care, extensive (although tissue-saving surgery) and antibiotics for 
SSTI patients14. The indication has been analyzed in a Cochrane report 11. Some of the 
difficulties in comparing the publications were found to be definition of the disease, 
different HBOT doses, non-standardized surgical procedures and standards for when to 
stop the HBO series. The possibility of monitoring oxygen changes in target tissues 
may help to solve some of these issues namely HBO dose and indicate when to stop 
HBOT.  
 
At Karolinska University Hospital we have used the triad of CRP below 100, no 
necessity of drugs to maintain MAP and the surgeons report there are no more 
production of necrotic tissue to define “infection control”. When the patient reaches 
infection control we stop HBOT unless there is a need to support the wound healing. 
 
If a scientific evaluation on the efficacy of oxygen is to be made there is a need for a 
standardized dose. Are studies of oxygen, not using an evidence-based dose, of any 
value? In some studies and a Cochrane report 37-38, 48-49 administration of oxygen has 
even been suggested to be negative for the patient rather than beneficial, can this be due 
to the low dose used?  
 
 
 
HBO side effects  
 
Patients breathing oxygen are exposed mainly to risk of central nervous system (CNS) 
and pulmonary oxygen toxicity 50. Oxygen seizures may occur, especially when therapy 
is administered at high pressures to patients with fever or when hypercapnia, often 
attributable to hypoventilation, is present. An incidence of 1/10,000 treatments is often 
cited. Seizures are self-limiting, and sequelae are uncommon.  A partial pressure of O2 
of 170 kPa (1.7 ATA ), as found in the nitrox mix (60.5% O2) used in the present study 
is higher than that recommended for use in commercial diving in water 51; NOAA 
recommends a maximum of 1.6 ATA , while the US NAVY recommends 1.3 ATA. 
However, it is lower than the 190 kPa used for attendants in U.S. Navy Table 6 52, one 
of our LTPs (study IV). The risk of CNS toxicity for attendants using nitrox, with 
intermittent air breaks at the proposed level in HOPAN (study IV) is considered very 
low 50, 53-54. 
 
When breathing oxygen at a higher pressure than in ambient air for an extended period 
of time, pulmonary oxygen toxicity has to be considered 50, 55-56. The toxicity to the 
lungs can be seen as a decrease in vital capacity and calculated as unit pulmonary 
toxicity dose (UPTD). The accumulative risk is limited by air breaks, common in most 
HBOT protocols. All HOPANs (study IV) were well within the Statute book of the 
Swedish National Board of Occupational Safety and Health regulations of UPTD for 
both patients and attendants (limit maximum 850 UPTD/day) 57-58.  
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Methodological considerations 
 
Study I 
A retrospective study although consecutive as to patients referred for HBOT because of  
a specific medical disorder (infections following neurosurgery) will never produce 
conclusive evidence of the usefulness of the intervention but can give valuable 
information to forthcoming study designs. This study started with one interested 
neurosurgeon, specialized in meningeomas, making the material deviate towards 
patients with meningeomas instead of a generalized neurosurgical population (Study I 
Table 1,2,3).  
At the time of the study the hyperbaric chamber location was very far from the 
neurosurgical clinic making the transport of critically ill patients a hazard. As the 
indication for HBO was additional and not earlier described we decided to exclude all 
critically ill patients. 
 
As experience of HBOT for these infections grew, a few more neurosurgeons took 
interest in the method and more complicated cases were referred. This made the 
material change during the study period from cleancut infections following surgery of 
meningeomas to infections in complicated cases following surgery of a diversity of 
disorders and including infections after spinal surgery. Diagnosis of an infection in 
bone tissue can also present a problem for cranial infections it is often based on the 
clinical presentation. X-ray or other forms of diagnostic imaging can rarely picture the 
infection until in the later stages 59-60 and blood samples are rarely conclusive. In order 
to find the correct pathogen for osteomyelitis a small sample of bone tissue to culture is 
required. 
 A bone sample is accompanied with a risk of complications and is therefore not 
included as a routine procedure, none of the patients in this study had such a sample 
taken.  
We can therefore not be sure that the bacterias in the cultures taken from the wound in 
the soft tissues of the scull or spinally (fig 5, in methods), mostly after onset of 
antibiotic therapy, are the tue pathogens. In several of the cases we found no bacteria in 
the cultures although the clinical symtoms of infection were convincing. 
 
 It is a clinical challenge to decide, on the clinical symtoms only, whether a superficial 
infection of skin and soft tissues or a deeper infection of bone is present. Endpoints are 
also difficult since there are no clinically available monitoring methods to decide 
whether the bone tissue is infected or not. In this study we continued HBOT initially up 
to 40 sessions and later until the wound was healed + 5 days. A method to monitor the 
status of the bone tissue could have made it possible to individualize the number of 
HBOT as it is our opinion that the soft tissues would have healed without the addition 
of HBOT once the infection in the bone was under control.  
 
The material has after the publication increased in volume, grown to include brain 
abscesses and infections following insertion of implants.  Although this has been 
presented as abstracts 16, 20, 61 and a publication 62 there is still a need for randomised, 
controlled studies to make the use of HBOT evidence-based.  
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Study II and III.  
Using technical equipment under hyperbaric conditions can put both the equipment and 
persons inside and outside the chambers at hazard. Most clinically available equipment 
have not been tested for hyperbaric use, the procedures for such tests are regulated by 
MPA/LMV in Sweden. The NIRS and PPG equipments used in our tests were not 
tested for hyperbaric use. The equipments were, prior to our use, tested in hyperbaric 
protocols by the medical technical department of Karolinska University Hospital. NIRS 
equipments are commercially available and in clinical use mostly in intensive care units 
63-64.  
We used the Inspectra equipment in our study but we also tested Somanetics equipment 
(with a pass-through in the chamber wall). The Inspectra NIRS monitor has been 
evaluated for use on the thenar eminence only; however, there are other NIRS monitors 
available with probes evaluated for use in other parts of the body. Our choice of 
monitor was made because it could be used safely inside the hyperbaric chamber. The 
Somanetics equipment was only tested on a few subjects to evaluate its feasibility for 
future studies. This equipment has a 4-channel parallel capacity making it possible to 
compare a healthy tissue on one side of a patient with infected target tissue on the other 
side.  
 
None of the equipments are, as of yet, commercially available for hyperbaric use.  
The protocol used with subjects first breathing NBO and then HBO at the same 
occasion may have influenced the results although we still have a reliable compliance 
between the monitored changes in StO2 and inhaled oxygen. 
 
The PPG method is quite new, not commercially available yet and its validation under 
further discussions 31, 65. Blood flow in most tissues is influenced by activity. In our 
study we used a 10 minute resting period before exposure 66, the correct resting time to 
down-regulate bone blood flow to base-line values is not known, the 10 minutes used 
by us may have been too short. A period covering at least 30-60 heartbeats has been 
suggested to improve confidence in PPG pulse measurements 27, the 10 minute period 
used in our study is well over this limit.  
The similar results in many studies using different measuring methods indicate that 
decreased blood flow is a valid immediate reaction in skin to increased oxygen tissue 
content in healthy subjects; it is not validated for oxygen content in bone.  
 
 
Study IV 
The new protocol was taken into clinical practise according to local routine, which at 
that time was that the protocol chosen was under the supervision of each senior 
hyperbaric specialist. There were several protocols in routine use.  
The HOPAN protocol was only used under the direction and presence of one of the 
authors, the selection of when and what patients to treat was therefore not according to 
severity or disorder. The evaluation was done retrospectively after HOPAN had been in 
use for a little more than one year.  
It is difficult to be conclusive when the patients have received an HBOT series which 
was random but not randomised with a variety of LTPs and HOPANs (fig 4 in 
methods). HOPAN could randomly be any (or all) of the treatments in a patients’ series 
of HBOT.  
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It was found to be comfortable and safe to breathe nitrox intermittently and perform 
patient care during air breaks, as the attendants are not used to mask breathing as the 
most often-used LTP does not use mask breathing at all. During the most common LTP 
(local treatment protocol) in our unit, attendants breathe chamber air throughout the 
protocol. Oxygen breathing for attendants is used during safety stops in the more rarely 
used 175-minute LT P and U.S. Navy treatment table 6.  
 
The questionnaire sent to attendants was sent after the study period was finished. This 
meant for some attendants that they received the questions within weeks of the HOPAN 
and for others a little more than a year after the HOPAN.  
As there was no documented symtoms or complications, in the HBO units records, to 
any of the LTPs it was presumed that these protocols never caused any problems. The 
questionnaire was contructed under this presumtion which unfortunately proved to be 
questionable.  
One of the difficulties is that there is no possibility to separate the different LTP 
protocols. Symptoms for attendants inside chamber, both minor (24/31) and severe 
(5/31 joint pain, VAS/NRS 1-8), were reported in connection with LTP, while no minor 
and one severe occurrence (1/31 joint pain, VAS/NRS 3) was reported in connection 
with HOPAN.  
It is very difficult to retrospectively evaluate possible symtoms of DCS that has not 
been documented or examamined. 
 
 
 
NIRS  
Lack of reliable and suitable monitoring methods of the oxygen content in the target 
tissues makes evaluation and dosage of HBOT difficult. 
To verify that HBOT does allow oxygen to reach the target tissues and also to evaluate 
at what dose it reverses tissue hypoxia, an efficacious measure of oxygen content in 
tissues is needed. As oxygen levels in tissues can change very quickly, in the order of 
minutes, monitoring should preferably be carried out during HBO administration. 
 
In a previous study, Litscher et al. 67 evaluated NIRS using a different type of monitor 
(INVOS 3100 cerebral oximeter) than the one we used (Inspectra) measuring cerebral 
oxygenation during HBO. They used a pass-through penetrator in the chamber wall, 
situating the monitor outside the chamber with the probe attached to the subjects inside 
chamber. Although the results of the Litscher study are similar to those of the present 
study, one difference is that on returning to ground level (21 kPa oxygen) following the 
period of HBO, at 15 min the NIRS values had still not returned to the baseline levels 
recorded prior to the increase in pressure. A possible explanation for this finding is that 
the StO2 measurements were made in two very different tissues—cerebrally in the 
Litscher study and in our study (study II), in peripheral muscle (thenar muscle); the 
difference in delay of return to baseline StO2 levels after HBO exposure presents an 
interesting issue for further tests.  
 
NIRS has not yet been evaluated for use under hyperbaric conditions. 
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PPG  
PPG is a non-invasive optical technique that measures changes in pulsatile blood flow 
and PPG has been used to monitor blood flow in skin and muscles 25-27, and to monitor 
hemodynamic sensing in implanted devices 28.  
It has been shown that experimental induced changes in pulsatile blood flow within the 
patellar bone are possible to study using the PPG technique 29-31.  Meiroviths et al 68 
showed that microcirculatory brain blood flow in rats decreased significantly in the first 
few minutes after HBO but returned to baseline levels within a variable period, still 
under HBO.  
 
Our results (study III) show similar results with a decreased blood flow initially. The 
effect of HBO on cerebral blood flow was though found to be highly dependent on the 
monitoring method, since other studies revealed no such systematic changes 69.  
An important limitation of the present PPG technique is the lack of a gold standard for 
calibration. PPG measurements can at present therefore only be reported as changes 
from one point in time to another.  
 
Hyperoxia-mediated vasoconstriction and, as a result, decreased blood flow has been 
shown to occur in most healthy vascular beds in animals and man 70. Studies have 
shown that exposure to HBO causes a general quick vasoconstriction and blood flow 
reduction in various organs in rats and humans 24. Vucetic et al 71 reports an overall 
reduction in human retina arterioles diameter of 10% after 10 min HBO (2.5 ATA), 
which corresponds with a 40% fall in blood flow.  
 
The immediate reactions of HBO on bone blood flow have not been studied (to our 
knowledge) prior to our study (III).  
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6 CONCLUSIONS AND FURTHER PERSPECTIVES 
 
We conclude that HBOT can be an alternative/adjunct to standard surgical procedures 
for many complicated cranial and spinal infectious problems.  Prospective trials are 
needed to assess the appropriate doses, the medical and economic implications of this 
new treatment regime. 
 
We found that the two non-invasive methods (NIRS and PPG) could be promising 
technologies to monitor oxygen changes in target tissues during NBO and HBO. Prior 
to the use of NIRS and PPG in clinical HBO practice, further test are necessary to 
ensure the correct safe and accurate use inside hyperbaric chambers.  
 
HOPAN protocols for HBOT enables long and flexible treatments to patients in 
multiplace chambers, similar to the protocols used for monoplace chambers, while 
maintaining the possibility of a direct decompression and exit.  
It appears that the HOPAN protocols did not cause any severe increases in side effects 
for patients or attendants. 
 
Prospective study 
We plan, as a post-doctoral study, to investigate the possible clinical benefits of the 
prolonged HBOT afforded by HOPAN.  
  
Ethical permission: Dnr 2008/2074-31/4.  
 
A prospective study of SSTI patients treated according to the Karolinska University 
Hospital protocol (approximately 15-20 patients/year). Patients are randomized to 
different HBOT protocols and monitored with NIRS and PPG to follow oxygen 
changes in target tissues.  
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